Who Novartis buys from and sells to
Swiss maker of patented drugs (Entresto, Kisqali, Cosentyx, Pluvicto radioligands); sells via wholesalers.
Buys from 0
None recorded
Where the chain could break
- Three largest customers were ~18%, 13% and 7% of 2025 net sales
- Entresto US generics from 2025 remove a top seller
Competes with
- Eli LillyLLYVerzenio against Kisqali in breast cancer
- AmgenAMGNRepatha against Leqvio in cholesterol
- AstraZenecaAZNoncology and cardiovascular drugs
Mapped by hand from filings and company reporting, as of October 2026. It shows the relationships that matter most, not every contract: most are never disclosed, and agreements change.